# ImmunoScape Pte

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immunoscape-pte

- Industry: Biotechnology
- Headquarters: Singapore, Singapore
- Website: www.immunoscape.com
- Total disclosed funding: $33M
- Latest round: Series B (Dec 8, 2022)
- Investors on record: 5

## About

ImmunoScape Pte Ltd is a biotechnology company focused on developing next-generation TCR-T cell therapies aimed at treating solid tumors in oncology, utilizing advanced technologies to enhance immune response against cancer.Founded in 2017 and headquartered in Singapore, ImmunoScape Pte Ltd specializes in pre-clinical biotechnology, concentrating on TCR-T cell therapies for oncology. The company has successfully raised a total of USD 20.42 mn through its funding efforts, with the latest Series B round completed on December 8, 2022, led by Anzu Partners. The founding team includes Choon Peng Ng, who serves as the CEO, and Evan Newell. The company has completed a total of 4 deals since its inception, indicating an active investment approach.ImmunoScape specializes in developing next-generation TCR-T cell therapies designed to effectively target solid tumors. The therapies aim to enhance the body's immune response against cancer cells, providing innovative treatment approaches for significant unmet medical needs. Their client base includes research institutions, healthcare providers, and pharmaceutical companies, with products being developed for markets including the United States, Europe, and Asia, extending their global reach beyond their operational bases in Singapore and San Diego.In 2023, ImmunoScape reported a revenue of USD 80.56 mn, alongside an EBITDA of USD -9,539,615, reflecting their business operations in the biotechnology sector and their financial performance in relation to their ongoing projects and partnerships.Following the completion of their Series B funding round in December 2022, in which ImmunoScape raised USD 20.42 mn, the company plans to use this capital to focus on advancing product development. The funding will support initiatives aimed at enhancing their TCR-T cell therapies and potentially launching new products in the coming years. Additionally, ImmunoScape is strategizing on expanding into new geographic markets, continuing to leverage growth opportunities in the United States, Europe, and Asia.

## Funding rounds

- Series B, Dec 8, 2022, $20M — Amgen Ventures, SG Growth Capital, Anzu Partners, NPR Holdings
- Series B, Feb 7, 2020, $11M — University of Tokyo Edge Capital Partners, Anzu Partners, NPR Holdings
- Series A, Jul 13, 2018, $2.4M — University of Tokyo Edge Capital Partners

## Investors

- University of Tokyo Edge Capital Partners (https://capitalatlas.ai/funds/university-of-tokyo-edge-capital-partners) — Series A, Series B
- Anzu Partners (https://capitalatlas.ai/funds/anzu-partners) — Series B
- NPR Holdings — Series B
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series B
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series B